Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.60 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358044 | 1.00 | SOS1 (0.60) | SOS1TNFCXCL8NOD2NOD1 | |
| SCHEMBL7338096 | 0.88 | SOS1 (0.49) | SOS1TNFCXCL8NOD2NOD1 | |
| SCHEMBL7298039 | 0.86 | ALDH1A1 (0.53) | SOS1TNFCXCL8NOD2NOD1 | |
| SCHEMBL7337916 | 0.85 | ALDH1A1 (0.65) | ALDH1A1POLBHTTCNR2CSF1R | |
| SCHEMBL7170787 | 0.85 | CNR2 (0.47) | SOS1TNFCXCL8NOD2NOD1 | |
| SCHEMBL7337406 | 0.81 | CNR2 (0.51) | SOS1DRD2CNR2CNR1P2RX3 | |
| SCHEMBL14521693 | 0.79 | CYP1A2 (0.55) | KMT2APOLBHTTCNR2CNR1 | |
| SCHEMBL2362142 | 0.77 | POLB (0.57) | ALDH1A1POLBHTTNUDT1BACE1 | |
| SCHEMBL7337702 | 0.76 | NOD1 (1.00) | SOS1TNFCXCL8NOD2NOD1 | |
| SCHEMBL5394735 | 0.75 | BACE1 (0.62) | SOS1TNFCXCL8NOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0545845-B1 | Imidazole compounds, their preparation and use as calcium channel blockers | NEUROSEARCH AS (DK) | 1996-02-28 | — | — | EP | claimed |
| US-5314903-A | Benzimidazole compounds useful as calcium channel blockers | NEUROSEARCH A/S (DK) | 1994-05-24 | — | — | US | claimed |
| EP-0545845-A1 | Imidazole compounds, their preparation and use as calcium channel blockers | NEUROSEARCH A/S (DK) | 1993-06-09 | — | — | EP | claimed |
| JP-7002796-A | — | — | None | — | — | JP | disclosed |
| US-20100234402-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-09-16 | — | — | US | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| EP-0545845-B1 | Imidazole compounds, their preparation and use as calcium channel blockers | NEUROSEARCH AS (DK) | 1996-02-28 | — | — | EP | disclosed |
| JP-H072796-A | IMIDAZOLE COMPOUND, ITS PREPARATION AND ITS USE | NEUROSEARCH AS | 1995-01-06 | — | — | JP | disclosed |
| US-5314903-A | Benzimidazole compounds useful as calcium channel blockers | NEUROSEARCH A/S (DK) | 1994-05-24 | — | — | US | disclosed |
| EP-0545845-A1 | Imidazole compounds, their preparation and use as calcium channel blockers | NEUROSEARCH A/S (DK) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | SOS1 4622/4885TNF 991/4885CXCL8 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.